

Redeye Initiates Coverage of PMD Device Solutions

Redeye initiates coverage of PMD Device Solutions, an Ireland-based company listed on the NASDAQ First North Growth Market following a reverse acquisition by Promore Pharma AB in December 2023. Its product "RespiraSense" was developed between 2011 and 2021, securing European approval in 2015 and US FDA approval in 2022. We expect strong growth in the upcoming 3-year period. The main catalysts for the stock are an extended English launch, higher virtual ward (hubs) contribution, and early 2025 contributions from Germany and the US.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Redeye Initiates Coverage of PMD Device Solutions